Trial Profile
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs HuMax IL8 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary) ; Celecoxib
- Indications Adenocarcinoma; Colon cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms NICHE
- 24 Oct 2023 According to Results presented at the 48th European Society for Medical Oncology Congress, accrual is currently ongoing in stage 2, in which an additional 40 patients will be treated.
- 24 Oct 2023 Results (n=19) of a prespecified analysis of pathologic response from stage 1 presented at the 48th European Society for Medical Oncology Congress
- 31 Jan 2023 Planned number of patients changed from 130 to 268.